| Melissa Griffin, BSN RN BMTCN | |
|
9160 Red Barn Way, Alexander, AR 72002-7041 | |
| (501) 909-2537 | |
| Not Available |
| Full Name | Melissa Griffin |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 9160 Red Barn Way, Alexander, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841916269 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | R040981 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Griffin, BSN RN BMTCN 9160 Red Barn Way, Alexander, AR 72002-7041 Ph: (501) 909-2537 | Melissa Griffin, BSN RN BMTCN 9160 Red Barn Way, Alexander, AR 72002-7041 Ph: (501) 909-2537 |
News Archive
According to the latest research in England, children who have a dog for a pet are less likely to be obese. Children who are obese in childhood are at increased risk of developing a range of chronic health problems such as high blood pressure, high cholesterol levels, bone and joint problems, asthma, disrupted sleep patterns, liver and gall bladder disease, early physical maturity and depression.
Imagine having an electrode embedded in your brain in a surgical procedure that involves drilling holes in your skull to implant it. Now imagine going through an MRI scan for medical evaluation, when the metal electrode may react to the magnetic fields and vibrate, generate heat or even possibly damage the brain.
The focus of his team was also on samples, in which the bacteria failed to respond to the agent. They discovered two types of resistance. "Spontaneous mutations can occur in the gene for dihydrofolate reductase rendering trimethoprim no longer able to attack the changed enzyme, which means it becomes ineffective," Nitsche-Schmitz explained.
MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART) products directed at two undisclosed cancer targets.
When people finish treatment for cancer, they want to bounce back to their former vital selves as quickly as possible. But a new Northwestern Medicine study - one of the largest survivor studies ever conducted - shows many survivors still suffer moderate to severe problems with pain, fatigue, sleep, memory and concentration three to five years after treatment has ended.
› Verified 9 days ago
Mrs. Holly Jo Jenkins, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2510 Crystal Lake Rd, Alexander, AR 72002 Phone: 501-993-0386 | |
Mrs. Jeannie Charmaine Roberts, R.N. Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1010 Silver Leaf Dr, Alexander, AR 72002 Phone: 501-909-9027 | |
Elizabeth Jean Shook, RNP, CS, APN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 5510 Oakbrook Rd, Alexander, AR 72002 Phone: 501-831-2751 | |
Elizabeth Heaggans, APRN Registered Nurse Medicare: Medicare Enrolled Practice Location: 7033 Gemstone Dr, Alexander, AR 72002 Phone: 501-215-0292 |